Palatin Technologies, Inc. (PTN)
NASDAQ: PTN · Real-Time Price · USD
7.77
-0.10 (-1.27%)
At close: Aug 7, 2026, 4:00 PM EDT
7.75
-0.02 (-0.30%)
After-hours: Aug 7, 2026, 5:55 PM EDT
Palatin Technologies Employees
Palatin Technologies had 29 employees as of June 30, 2025. The number of employees decreased by 1 or -3.33% compared to the previous year.
Employees
29
Change (1Y)
-1
Growth (1Y)
-3.33%
Revenue / Employee
$444,285
Profits / Employee
-$215,487
Market Cap
14.02M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2025 | 29 | -1 | -3.33% |
| Jun 30, 2024 | 30 | -4 | -11.76% |
| Jun 30, 2023 | 34 | 1 | 3.03% |
| Jun 30, 2022 | 33 | 7 | 26.92% |
| Jun 30, 2021 | 26 | 6 | 30.00% |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Passage Bio | 24 |
| Citius Pharmaceuticals | 23 |
| OSR Health | 22 |
| Lipocine | 14 |
| Tvardi Therapeutics | 12 |
| NewcelX | 12 |
| Akari Therapeutics, | 6 |
| Pasithea Therapeutics | 5 |
PTN News
- 1 day ago - StreetWatch: A $2.9 Billion Takeover Put a Spotlight on Relentless Hunger. Palatin Technologies Is Developing the Next Generation of the Drug That Seeks to Treat It - Newsfile Corp
- 6 weeks ago - Palatin Technologies Proxy statement: Proxy filing - Filings
- 7 weeks ago - Palatin Technologies Is Pursuing the Next Generation of MC4R. ... - GuruFocus
- 2 months ago - Palatin Technologies Slides: Corporate presentation - Filings
- 2 months ago - Palatin announces approval of its common stock by Nasdaq - TheFly
- 2 months ago - Palatin to Begin Trading on Nasdaq Stock Exchange - PRNewsWire
- 3 months ago - Palatin price target lowered to $47.50 from $50 at Alliance Global - TheFly
- 3 months ago - Palatin Technologies Earnings Call Transcript: Q3 2026 - Transcripts